T1	Participants 29 45	multiple myeloma
T2	Participants 164 230	Eastern Cooperative Oncology Group phase III E9486 clinical trial.
T3	Participants 785 936	There were 628 patients who were eligible for the clinical protocol E9486, but of these 521 were also entered on the companion laboratory study (E9487)
